Yellow fever vaccine

Yellow fever vaccine
Name	Yellow fever vaccine
Type	Live attenuated
Target	Yellow fever virus
Vaccine type	Live attenuated
Inventor	Max Theiler
Tradename	17D, Stamaril, YF-VAX
Legal status	WHO prequalified (selected formulations)

Yellow fever vaccine is a live attenuated preparation used to prevent Yellow fever caused by the Yellow fever virus in humans. Developed in the 20th century, the vaccine has been central to control efforts in South America, Sub-Saharan Africa, and during outbreaks affecting travelers to Central America and West Africa. It is produced in several formulations and recommended by the World Health Organization and national health agencies for residents and travelers to endemic areas.

History

The modern vaccine traces to work by Max Theiler at the Rockefeller Foundation in the 1930s, who developed the 17D strain and earned the Nobel Prize in Physiology or Medicine. Early field campaigns involved collaborations among the Pan American Health Organization, Centers for Disease Control and Prevention, and national ministries in Brazil, Nigeria, and Ghana. Mass vaccination campaigns accompanied programs such as the Yellow Fever Initiative and emergency responses during outbreaks in Angola and Democratic Republic of the Congo. Research on vaccine safety and dose-sparing strategies has involved institutions including Pasteur Institute and Walter Reed Army Institute of Research.

Vaccine composition and types

Current licensed preparations derive from the 17D live attenuated strain subtypes (commonly 17D-204 and 17DD) produced in embryonated Gallus gallus domesticus eggs or cell substrates. Commercial trade names include Stamaril and YF-VAX, produced by manufacturers regulated under authorities such as the European Medicines Agency and Food and Drug Administration. Formulations may be single-dose lyophilized vials reconstituted with buffered diluent; some regulatory dossiers describe variations in antigenic content measured by plaque-forming units (PFU). Production and quality control reference standards have been coordinated through collaborations between World Health Organization reference laboratories and national institutes like the National Institutes of Health.

Efficacy and immune response

A single dose of 17D-based vaccine induces robust neutralizing antibodies in most recipients within 10 days and high seroconversion rates by 30 days, demonstrated in clinical trials overseen by London School of Hygiene & Tropical Medicine, University of São Paulo, and University of Oxford. Correlates of protection include neutralizing antibody titers measured by plaque reduction neutralization tests standardized against WHO reference sera. Durable immunity has been observed in long-term cohort studies by investigators affiliated with Harvard University and University of Cape Town, prompting policy shifts by World Health Organization from routine booster requirements to single-dose lifelong recommendations for most populations.

Safety and adverse effects

Local reactogenicity (injection-site pain, low-grade fever) is common and documented in post-marketing surveillance coordinated by European Centre for Disease Prevention and Control and Pan American Health Organization. Rare serious events include yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and yellow fever vaccine-associated neurotropic disease (YEL-AND), identified in case series compiled by Centers for Disease Control and Prevention and national pharmacovigilance centers. Risk factors for severe adverse events reported in cohort analyses include advanced age, thymus disorders, and certain immunodeficiencies evaluated at centers like Mayo Clinic and Johns Hopkins Hospital. Regulatory agencies such as the Food and Drug Administration maintain contraindication guidance and safety communications.

Indications and contraindications

Indications include travel to or residence in areas with risk of yellow fever transmission as defined by World Health Organization maps, and laboratory personnel working with Flavivirus isolates in reference laboratories such as CDC facilities. Contraindications include significant immunosuppression (e.g., recipients of high-dose corticosteroids, hematopoietic stem cell transplant patients), severe allergy to egg proteins evaluated by allergists at institutions like Cleveland Clinic, and infants below recommended age thresholds established by national immunization programs in United Kingdom and Brazil. Special use considerations for pregnant or breastfeeding persons have been addressed in guidelines by WHO and national advisory committees.

Administration and dosing

Standard administration is a single intramuscular or subcutaneous injection of reconstituted vaccine. Dose volume and PFU specifications are outlined in product monographs approved by regulatory authorities such as the European Medicines Agency and Food and Drug Administration. Booster dosing policies have evolved following retrospective analyses by WHO Strategic Advisory Group of Experts on Immunization (SAGE) and cohort studies from Ghana and Ethiopia, with booster recommendations reserved for select high-risk groups and required documentation for entry under the International Health Regulations via the International Certificate of Vaccination or Prophylaxis.

Global use and public health impact

Yellow fever vaccination campaigns have markedly reduced urban outbreaks in Lagos, Rio de Janeiro, and Kinshasa and contributed to regional elimination goals supported by Gavi, the Vaccine Alliance, Pan American Health Organization, and national ministries of health. Vaccine stockpiles managed through WHO emergency frameworks have been deployed during epidemics in Angola and Democratic Republic of the Congo to curb transmission. Ongoing challenges include manufacturing capacity constraints, cold chain logistics overseen by organizations like UNICEF, and integration with routine immunization schedules in endemic countries such as Uganda and Senegal.

Category:Vaccines